PO.PS01.10 · 人群科学

COVID-19期间性少数与性别少数(SGM)癌症幸存者中筛查/照护延迟与频繁精神困扰的影响

Impact of delayed screening/care and frequent mental distress during COVID-19 among SGM cancer survivors

海报缩略图:COVID-19期间性少数与性别少数(SGM)癌症幸存者中筛查/照护延迟与频繁精神困扰的影响
编号 857 展板 3 时间 4/19 02:00–05:00 区域 Section 34 主讲 John Fuller, BS
分会场 Survivorship Research
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

John A. Fuller, Jessica Wells

Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA

摘要 Abstract

中文摘要
目的:与顺性别异性恋幸存者相比,性少数与性别少数(SGM)幸存者被诊断为晚期癌症的风险显著更高,这可能是由于历史上被排除在筛查之外以及更多地从事吸烟、酗酒和高风险性行为等风险行为。医疗环境中的歧视、污名化和少数群体压力限制了其获得筛查、照护和治疗的机会,并加剧了精神困扰。延迟与心理健康之间的联系尚不明确。本研究考察了COVID-19期间SGM幸存者中筛查/照护延迟与频繁精神困扰(FMD)之间的关联。 方法:我们使用了OUT: The National Cancer Survey的二手数据,这是一项于2020年9月至2021年3月对美国成年SGM癌症幸存者进行的在线问卷调查。参与者自我报告筛查/照护延迟情况(编码为"是"、"否"或"否,不适用")以及过去一个月中精神状态不佳的天数(自由文本回答)。FMD采用美国疾病控制与预防中心(CDC)验证的临界值(即过去30天中≥14天精神状态不佳)作为二分类结局进行分析。鉴于年龄对心理健康结局的既定影响,将其作为协变量纳入。进行了描述性统计、双变量相关性分析以及带敏感性分析的逻辑回归。 结果:参与者(N = 2,073)的平均年龄为58.69岁(SD = 11.12)。报告的精神状态不佳天数范围为0至30天,平均为9.88天(SD = 10.75)。筛查/照护延迟与FMD显著相关。报告筛查/照护延迟的参与者中有37.5%经历了FMD,而未报告延迟者中这一比例为49.6%(p < 0.001)。多变量回归分析显示,筛查/照护延迟和年龄是FMD的显著预测因素。报告筛查/照护延迟的参与者经历FMD的可能性比未报告延迟者高84%(OR = 1.84,95% CI:1.41-2.41,p < 0.001)。年龄与FMD呈负相关,年龄每增加一岁,经历FMD的几率降低4%(OR = 0.96,95% CI:0.95-0.97,p < 0.001)。 结论:本研究凸显了导致SGM癌症幸存者在癌症筛查、照护和治疗方面延迟的健康社会决定因素。未来研究应侧重于指导肿瘤科医护人员制定有针对性的策略,以改善边缘化群体的心理健康结局,尤其是在COVID-19大流行等医疗中断加剧的时期。
查看英文原文 English abstract
Purpose: Sexual and gender minority (SGM) survivors have a significantly higher risk of late-stage cancer diagnosis compared with cisgender-heterosexual survivors, possibly due to historical exclusion from screening and higher engagement in risk behaviors like smoking, binge drinking, and risky sexual practices. Discrimination, stigma, and minority stress in healthcare settings limit access to screening, care, and treatment and contribute to increasing mental distress. The link between delays and mental health is unclear. This study examines the association between delayed screening/care and frequent mental distress (FMD) during COVID-19 among SGM survivors. Methods: We utilized secondary data from OUT: The National Cancer Survey, an online questionnaire administered to U.S. adult SGM cancer survivors from September 2020 to March 2021. Participants self-reported delayed screening/care (coded as “Yes,” “No,” or “No, not applicable”) and the number of poor mental health days (free-text response) in the past month. FMD was analyzed as a binary outcome using a Centers for Disease Control and Prevention (CDC)-validated cutoff (i.e., 14 or more PMHD in the last 30 days). Age was included as a covariate, given its established impact on mental health outcomes. Descriptive statistics, bivariate correlations, and logistic regression with sensitivity analyses were performed. Results: On average, participants (N = 2,073) were aged 58.69 years (SD = 11.12). The number of poor mental health days reported ranged from 0 to 30, with an average of 9.88 days (SD = 10.75). Delayed screening/care was significantly associated with FMD. 37.5% of participants reported delayed screening/care experienced FMD, compared to 49.6% of those who did not (p < 0.001). Multivariable regression analysis revealed that delayed screening/care and age were significant predictors of FMD. Participants who reported delayed screening/care were 84% more likely to experience FMD compared to those who did not report delayed screening/care (OR = 1.84, 95% CI: 1.41-2.41, p < 0.001). Age was inversely associated with FMD, with each additional year of age reducing the odds of experiencing FMD by 4% (OR = 0.96, 95% CI: 0.95-0.97, p < 0.001). Conclusion: This study highlights the social determinants of health contributing to delays in cancer screening, care, and treatment among SGM cancer survivors. Future research should focus on guiding oncology providers in developing targeted strategies to improve mental health outcomes among marginalized communities, especially during periods of increased healthcare disruption like the COVID-19 pandemic.
利益披露 Disclosure
J. A. Fuller, None.. J. Wells, None.

← 返回 AACR 2026 检索